GLAS
Global Loan Agency Services Limited (part of the global GLAS Group) is thrilled to announce the successful completion of its acquisition of Pristine. This marks the first acquisition by the GLAS Group, and also represents a key milestone in the organisation’s ambitious roadmap to deepen its presence in Europe.
This transaction was agreed in August 2023 subject to regulatory approval and customary closing conditions, with completion occurring in March 2024.
Pristine
Pristine is a leading fiducie and asset management business. It was established in Paris in 2016 and is regulated by the Autorité des Marchés Financiers (AMF).
Pristine provides a complementary set of services which include fiducie, fund structuring and administration services to both international and domestic institutions with the primary purpose of facilitating corporate financing activity for non-bank and bank lenders in France.
The firm has a deep and diversified history in restructuring, securitisation, structured finance, and other ad hoc financing projects.
GLAS France
The GLAS Group launched its French operations in Paris in 2018 and has since built out a sizeable team led by Aymeric Mahe, Head of GLAS SAS.
GLAS SAS is the only non-bank, independent company regulated by the Autorité de Contrôle Preduentiel et de Résolution (ACPR) to administer payments in France on loan transactions that forms part of a global group.
In addition to loan agency services, GLAS provides a range of institutional debt administration to domestic and international debt funds, corporates, and bulge bracket banks globally.
The firm is a market-leading provider in direct and syndicated lending, high yield, leveraged finance and capital market debt issuance.
GLAS SAS has also been involved with numerous high-profile restructuring cases in France such as SMCP, Orpea, Technicolor and Pierre & Vacances.
GLAS founders Mia Drennan and Brian Carne said:
“We are excited to finalise the Group’s first ever acquisition and further expand GLAS’s service capabilities. The AMF and ACPR regulatory permissions of Pristine and GLAS, along with our collective expertise and reputations in the debt markets, will allow us to offer an expanded offering of relevant services to our enlarged client base.”
Pristine Président, Renaud Baboin said:
“This acquisition signals the start of a fantastic partnership between GLAS and Pristine. The two companies are well matched across all aspects of the respective businesses and culture, and I am excited to see how the respective businesses flourish as a result."
Pristine Directeur Général, Benjamin Raillard added:
“We are happy to announce the closure of this transaction and begin integrating Pristine with the GLAS Group. It is an exciting time for the group and our customers who will soon be able to benefit from the synergies of the two organisation’s expertise. We are confident that this partnership will be a fruitful one for all involved.”
GLAS and Pristine’s plan for the future
The conclusion of this acquisition signifies GLAS’s commitment to offering an expanded suite of products and services to meet the needs of clients who participate in originating debt or investing in financial transactions in Europe.
The Pristine team will be located at GLAS SAS’s new Paris office on Avenue George V.
The two organisations will be continue to be separately regulated by the AMF and the ACPR. The two licences will allow GLAS and Pristine to offer an enhanced service to more customers on a greater number of transactions.
Since the original announcement of the proposal to acquire Pristine, GLAS have also, subject to regulatory approval, committed to partnering with Singaporean-based Watiga. Watiga will also join the GLAS Group’s global network.
About GLAS
GLAS was established in 2011 by Mia Drennan and Brian Carne. Today, it is the premier independent, non-creditor, conflict-free provider of loan administration and bond trustee services known for its white glove service and expertise on complex deal execution.
GLAS is a global company and is located in the USA, Europe, and APAC, with headquarters in London. GLAS services in excess of €360bn of assets under administration on a daily basis and employs over 300 professionals in the Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401726218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom